SOP: Good Distribution Practice and the Distribution Quality System

This is a ready-to-use SOP for the overarching distribution quality system that sits above the individual GDP procedures (mapping, lane qualification, excursion disposition, returns, recall). Replace every <<FILL: ...>> placeholder, set your document numbers and dates, and route it through document control. A filled specimen follows. Verify each cited reference against the current source before you rely on it.

Document control header

1. Purpose

This procedure defines how <<FILL: COMPANY NAME>> keeps medicinal product within its registered quality, safety, and efficacy from release through to the patient-facing dispenser, and how the distribution quality system is governed. It controls the four distribution hazards: degradation (temperature, light, humidity, shock), loss or theft, diversion, and falsified product entering the legitimate chain.

2. Scope

This procedure applies to storage, handling, and transport of finished medicinal product at the sites listed in the header and by contracted third-party logistics providers and carriers acting on the company’s behalf. It governs the distribution quality system as a whole and references the detailed procedures for temperature mapping, lane qualification, excursion disposition, returns, and recall.

3. Responsibilities

4. Definitions

• Responsible Person (RP): the named individual accountable for the distribution quality system under the applicable GDP framework. In jurisdictions without a statutory RP, the equivalent named, independent quality decision-maker.
• Authorized party: a manufacturer, wholesaler, broker, or dispenser that holds the required licence or registration to be a source or recipient of product.
• Excursion: any monitored storage or transport reading outside the labeled range.
• Saleable return: returned product proposed for return to sellable stock, permitted only when defined conditions are met and authorized.

5. Procedure

5.1 Named accountability

1. Appoint a Responsible Person (or equivalent) in writing, with the authority, independence, and competence to stop product from shipping.
2. Maintain a delegation chain so the role is continuously covered.
3. Keep the RP’s decisions (excursion dispositions, recall decisions, saleable-return authorizations) personally signed and dated.

5.2 Authorized sourcing and supply

1. Qualify every supplier and customer as an authorized party before transacting; re-verify on a defined cadence (<<FILL: SOP-ID for supplier qualification>>).
2. Where a track-and-trace regime applies (US DSCSA, EU FMD), exchange or verify the required identifiers and records at each change of ownership (<<FILL: SOP-ID for serialization>>).
3. Handle any suspect or illegitimate product through the defined quarantine, investigation, and notification workflow rather than returning it to stock.

5.3 Storage and transport control

1. Store product within its labeled conditions in qualified, monitored areas; place permanent monitors on the worst-case locations identified by temperature mapping (<<FILL: protocol-ID for mapping>>).
2. Ship only on qualified packaging-and-lane configurations, within the maximum qualified transit time and season (<<FILL: protocol-ID for lane qualification>>).
3. Bind carriers contractually to the qualified transit limits and to excursion-notification timelines (<<FILL: SOP-ID for quality agreements>>).

5.4 Excursion governance

1. On any excursion, quarantine the affected stock and disposition it against the product’s documented stability allowances, tracking the cumulative excursion budget (<<FILL: SOP-ID for excursion disposition>>).
2. The RP or a delegate makes and signs the disposition; freeze excursions on products with no cold-side budget default to reject.
3. Trend excursions by lane, shipper, and zone into CAPA.

5.5 Returns and recalls

1. Accept a return to saleable stock only when in-range storage was demonstrable for the entire time out of the company’s control, packaging is intact, product is in date, and the identifier is verifiable; the RP or delegate authorizes (<<FILL: WI-ID for saleable returns>>).
2. Treat unmonitored returns as non-saleable by default.
3. Execute recalls to the consignee level with documented reconciliation of shipped versus retrieved quantities (<<FILL: SOP-ID for recall>>).

5.6 Self-inspection and management review

1. Run periodic GDP self-inspections covering mapping-to-monitoring traceability, lane qualification, excursion rigor, named accountability, recall reach, and serialization integrity (<<FILL: CHK-ID for GDP self-inspection>>).
2. Feed distribution trends into management review.

6. Acceptance criteria

• A named, independent, continuously covered RP (or equivalent) is exercising the role, with signed dispositions and recall decisions.
• Product moves only among authorized parties, with the applicable serialization records exchanged or verified.
• Storage and transport occur only within qualified, monitored conditions and lanes.
• Excursions are quarantined, dispositioned against stability with cumulative-budget tracking, and signed by quality.
• Returns meet the saleable conditions or are routed to destruction; recalls reach the consignee level with reconciliation.

7. References

EU Guidelines on Good Distribution Practice (2013/C 343/01), referenced by Directive 2001/83/EC. MHRA “Rules and Guidance for Pharmaceutical Distributors” (the Green Guide). 21 CFR 211.142 and 211.150 (holding and distribution); 21 CFR Part 205 (state wholesale licensing). Drug Supply Chain Security Act (Title II of the Drug Quality and Security Act 2013). EU GMP Annex 15 (qualification and validation) and ICH Q9(R1) (quality risk management). PIC/S PE 011 (Good Distribution Practice) and WHO TRS guidance on storage and transport.

Confirm the current version and clause numbers of each reference before issue. This procedure is educational guidance to adapt, not legal or regulatory advice.

8. Records generated

• RP appointment and delegation records.
• Excursion dispositions and cumulative-budget ledgers.
• Saleable-return authorizations and recall reconciliation records.
• GDP self-inspection reports and management review minutes.

9. Revision history

10. Approvals

Filled specimen

Illustrative extract of the named-accountability and excursion-governance records for one operation. Names and numbers are examples.

• RP appointment: R. Okafor named Responsible Person on WDA <<FILL>>, appointment letter 04 Jan 2026; deputy S. Lindqvist, delegation matrix DIST-DEL-01 covers absence.
• Excursion disposition (worked): 2-8 C biologic, lot L-2607; tarmac hold peaked 19 C for 5 h. Cumulative budget 5.6 of 48 h used, no freeze. RP released for continued distribution, signed 22 Jun 2026, budget carried forward on the lot history; tarmac-hold cause opened as CAPA-DIST-2026-014.
• Saleable return refused: unit returned from a clinic with no temperature record for 26 h out of control; failed the first gate (thermal history not demonstrable); routed to destruction, RP authorized, 28 Jun 2026.

The refused return is the teaching case: a distributor cannot reconstruct a thermal history after the fact, so absence of data is itself the finding, and the default is non-saleable.

Common inspection findings this SOP prevents

• No named, independent RP actually exercising the role, or no delegation chain for absences.
• Product shipped on lanes or shippers never qualified for the real transit time.
• Excursions released on a blanket “within stability” statement with no cumulative-budget math.
• Unmonitored returns restocked without demonstrable thermal history.
• Quality agreements with logistics providers silent on temperature responsibility and excursion-notification timelines.

How to adapt this SOP

1. Set your document number, RP role title, and effective date in the header.
2. Point the cross-references in section 5 to your real mapping, lane, excursion, returns, and recall procedures.
3. For US-only operations without a statutory RP, name the equivalent independent quality decision-maker and keep the same authority and independence expectations.
4. Confirm every reference in section 7 against the current published version before issue.